Overview

NABOTA® is a high-purity Botulinum Toxin Type A formulation developed by Daewoong Pharmaceuticals. FDA-approved and backed by multiple clinical trials, it delivers reliable, temporary smoothing of moderate to severe dynamic wrinkles.

Composition

• Clostridium botulinum toxin type A: 200 U
• Human serum albumin: 0.5 mg
• Sodium chloride: 0.9 mg

Appearance & Reconstitution

Supplied as a white-to-light-yellow lyophilisate in a clear vial. Reconstitute with sterile, preservative-free 0.9 % saline to achieve 4 U/0.1 mL (200 U/5 mL). Gently swirl; avoid agitation. Label with date/time and use within 24 hours.

Mechanism of Action

NABOTA® inhibits acetylcholine release at neuromuscular junctions, producing localized muscle relaxation that softens expression lines and relieves hyperactive muscle conditions.

Indications

Aesthetic

• Temporary improvement of moderate to severe glabellar lines
• Forehead lines
• Crow’s feet
• Periorbital and perioral wrinkles

Therapeutic

• Chronic migraine prevention
• Neurogenic detrusor overactivity (urinary incontinence)
• Axillary hyperhidrosis

Administration

Inject intramuscularly using a 30–33 G needle. Tailor dose and injection sites to individual anatomy and treatment goals. Typical interval between treatments is 3–6 months.

Storage & Shelf Life

Store unopened vials at 2–8 °C; do not freeze. Maintain aseptic handling of reconstituted product. Shelf life: 36 months from manufacture.

Safety & Precautions

Administer only by licensed professionals. Inspect solution for particulate matter and discoloration before use. Contraindicated in patients with known hypersensitivity to any component. Common adverse events include injection-site discomfort, localized weakness, and transient ptosis. Serious systemic effects are rare but warrant prompt medical attention.